NERV News and Press, Minerva Neurosciences Inc From 08/24/22

Minerva Neurosciences ( NASDAQ: NERV ) is up 75% in Wednesday afternoon trading following an SEC filing stating that Point72 Capital Advisors has an 8.8% stake in the company. The company reached a high today of $8.58 per share, though that is still well below the ...

Minerva Neurosciences ( NASDAQ: NERV ) is up 42% in Wednesday morning trading following an SEC filing stating that Point72 Capital Advisors has an 8.8% stake in the company. The filing, posted after Tuesday's closing bell, states that Point72 has 470K outstanding s...

Penny stocks typically trade for less than $5 per share and tend to be highly volatile. But this wild price action has attracted so many retail traders over time. Whether we’re talking about OTC penny stocks or ones trading on the NYSE or NASDAQ, there are hundreds to choose from...

Minerva Neurosciences ( NASDAQ: NERV ) filed an application to the U.S. Food and Drug Administration (FDA) seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. The company's new drug application (NDA) was backed by data from ...

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the company has submitted a New Drug App...

Minerva Neurosciences press release ( NASDAQ: NERV ): Q2 GAAP EPS of -$1.63. Cash, cash equivalents and restricted cash as of June 30, 2022 and December 31, 2021 were approximately $49.9 million and $60.9 million, respectively. For further details see: Minerva Ne...

WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for...

Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...

Gainers: InVivo Therapeutics Holdings ( NVIV ) +164% . ChemoCentryx ( CCXI ) +109% . Minerva Neurosciences ( NERV ) +104% . Missfresh ( MF ) +66% . Society Pass ( SOPA ) +49% . Greenpro Capital ( GRNQ ) +48% . Yel...

Gainers: Global Blood Therapeutics ( GBT ) +33% . Yellow ( YELL ) +27% . Pactiv Evergreen  ( PTVE ) +17% . Minerva Neurosciences ( NERV ) +13% . MercadoLibre ( MELI ) +13% . Losers: Poseida Therapeutics ( PSTX ) ...